Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECAMYLAMINE HYDROCHLORIDE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
FDA: Management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension.,Off-label: Treatment of Tourette syndrome, tics, and as an adjunct in smoking cessation.
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant.
~10-20% bound to plasma proteins (primarily albumin).
Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Contraindicated in patients with renal insufficiency (e GFR <30 m L/min). For mild to moderate impairment, reduce dose by 50% and monitor closely.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not recommended for use in children due to lack of safety and efficacy data.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None.
None
May cause orthostatic hypotension, syncope, and impaired mental alertness.,Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.,Risk of rebound hypertension upon abrupt discontinuation.,Mecamylamine may precipitate urinary retention in patients with bladder dysfunction.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to mecamylamine or any component.,Coronary artery disease (risk of precipitation of angina).,Recent myocardial infarction.,Glaucoma (may increase intraocular pressure).,Uremia.,Concurrent use with ganglionic blocking agents.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid excessive alcohol intake as it may potentiate hypotensive effects. No specific food restrictions beyond maintaining a balanced diet.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No established pregnancy-specific dose adjustments. Use lowest effective dose due to volume of distribution and clearance changes (increased plasma volume, renal clearance). Monitor closely for hypotension; consider dose reduction if significant maternal hypotension occurs.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Mecamylamine is a non-competitive antagonist of nicotinic acetylcholine receptors, used primarily for hypertension. It does not affect parasympathetic ganglia at therapeutic doses. Caution in patients with renal impairment as drug accumulation occurs. Avoid use in patients with glaucoma or pyloric stenosis due to anticholinergic effects.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not skip doses or double up on missed doses.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it can cause dizziness or blurred vision.,Report any signs of slow heart rate, fainting, difficulty urinating, or blurred vision to your healthcare provider immediately.,Do not stop taking this medication abruptly; your blood pressure may rise rapidly.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
"Mecamylamine, a noncompetitive nicotinic acetylcholine receptor antagonist used for hypertension, potentiates the vasodilatory effects of Manidipine, a dihydropyridine calcium channel blocker, by reducing sympathetic reflex responses that normally counteract calcium channel blocker-induced hypotension. This additive hypotensive effect can lead to severe hypotension, dizziness, syncope, and increased risk of falls or cardiovascular events, particularly in elderly patients or those with volume depletion."
"Mecamylamine, a noncompetitive antagonist of nicotinic acetylcholine receptors, blocks sympathetic ganglionic transmission, leading to reduced catecholamine release and hypotension. Phentolamine, a nonselective alpha-adrenergic antagonist, further inhibits vasoconstriction mediated by norepinephrine. Concurrent use results in additive hypotensive effects, increasing the risk of severe hypotension, orthostatic dizziness, and syncope, particularly during initial dosing or dose escalation."
"Mecamylamine, a ganglionic blocker, antagonizes nicotinic acetylcholine receptors, leading to sympatholytic effects. Nabilone, a synthetic cannabinoid, can increase heart rate via central sympathetic activation. The interaction results in Mecamylamine augmenting the tachycardic effects of Nabilone, potentially causing excessive heart rate elevation and risk of cardiac stress."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECAMYLAMINE HYDROCHLORIDE vs ALDOMET, answered by our medical review team.
MECAMYLAMINE HYDROCHLORIDE is a Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECAMYLAMINE HYDROCHLORIDE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECAMYLAMINE HYDROCHLORIDE is: Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECAMYLAMINE HYDROCHLORIDE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECAMYLAMINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of ter. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.